A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 5, 2007, Pages 556-561

  Cazzola, Mario ^a   Andò, Filippo ^b   Santus, Pierachille ^c   Ruggeri, Paolo ^b   Di Marco, Fabiano ^c   Sanduzzi, Alessandro ^d   D'Amato, Maria ^e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

Author keywords

Combination therapy; COPD; Dyspnea; Fluticasone propionate; Lung function; Salmeterol; Tiotropium

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; SALBUTAMOL; TIOTROPIUM BROMIDE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; INHALER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROAT DISEASE; THRUSH; VISUAL ANALOG SCALE; XEROSTOMIA;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 34447498332     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.06.001     Document Type: Article

References (26)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Bethesda: National Heart, Lung and Blood Institute; April 2001. Update of the Management Sections, GOLD website 2005. Available at 〈www.goldcopd.com〉, accessed November 3, 2005.
2. Tashkin D.P., and Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 125 (2004) 249-259
3. Cazzola M., Di Marco F., Santus P., Boveri B., Verga M., Matera M.G., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 17 (2004) 35-39
4. Cazzola M., Centanni S., Santus P., Verga M., Mondoni M., di Marco F., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 98 (2004) 1214-1221
5. Cazzola M., Noschese P., Salzillo A., De Giglio C., D'Amato G., and Matera M.G. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 99 (2005) 524-528
6. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 (2005) 214-222
7. Soriano J.B., Vestbo J., Pride N.B., Kiri V., Maden C., and Maier W.C. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20 (2002) 819-825
8. Cazzola M., Di Lorenzo G., Di Perna F., Calderaro F., Testi R., and Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 118 (2000) 1576-1581
9. Mahler D.A., Wire P., Horstman D., Chang C.N., Yates J., Fischer T., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 1084-1091
10. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
11. Dal Negro R.W., Pomari C., Tognella S., and Micheletto C. Salmeterol & fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 16 (2003) 241-246
12. Hanania N.A., Darken P., Horstman D., Reisner C., Lee B., Davis S., et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 124 (2003) 834-843
13. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
14. Calverley P.M., Boonsawat W., Cseke Z., Zhong N., Peterson S., and Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003) 912-919
15. Cazzola M., Noschese P., Centanni S., Santus P., Di Marco F., Spicuzza L., et al. Salmeterol/fluticasone propionate in a single inhaler device versus theophylline+fluticasone propionate in patients with COPD. Pulm Pharmacol Ther 17 (2004) 141-145
16. Cazzola M., and Matera M.G. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest 125 (2004) 9-11
17. American Thoracic Society. Standardization of spirometry, 1987 update. Am Rev Respir Dis 136 (1987) 1285-1298
18. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320 (2000) 1297-1303
19. ICH harmonised tripartite guideline: clinical safety data management; definitions and standards for expedited reporting (recommended for adoption at step 4 of the ICH process on 27 October 1994 by the ICH steering committee). Available at 〈www.ich.org〉, accessed November 3, 2005.
20. 2-agonists and corticosteroids in stable COPD. Chest 126 (2004) 220-237
21. Emala C.W., Clancy J., and Hirshman C.A. Glucocorticoid treatment decreases muscarinic receptorexpression in canine airway smooth muscle. Am J Physiol 272 (1997) L745-L751
22. Jacoby D.B., Yost B.L., Kumaravel B., Chan-Li Y., Xiao H.Q., Kawashima K., et al. Glucocorticoid treatment increases inhibitory M2 muscarinic receptor expression and function in the airways. Am J Respir Cell Mol Biol 24 (2001) 485-491
23. Mahler D., Guyatt G.H., and Jones P.W. Clinical measurement of dyspnea. In: Mahler D. (Ed). Dyspnea (1998), Marcel Dekker, New York 149-198
24. Adams L., Chronos N., Lane R., and Guz A. The measurement of breathlessness induced in normal subjects: validity of two scaling techniques. Clin Sci 69 (1985) 7-16
25. Noseda A., Schmerber J., Prigogine T., and Yernault J.C. How do patients with either asthma or COPD perceive acute bronchodilation?. Eur Respir J 6 (1993) 636-644
26. Freiman J.A., Chalmers T.C., Smith H., and Kuebler R.R. The importance of β, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med 299 (1978) 690-694